Literature DB >> 20676602

[Structures of neurooncological science and care].

W Wick1, M Weller.   

Abstract

Mesh：

Year:  2010        PMID： 20676602     DOI： 10.1007/s00115-010-2953-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  8 in total

1.  German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.

Authors:  Ulrich Herrlinger; Martin Schabet; Wolfram Brugger; Rolf-Dieter Kortmann; Wilhelm Küker; Martina Deckert; Corinna Engel; Hans-Jürgen Schmeck-Lindenau; Hans-Günther Mergenthaler; Peter Krauseneck; Christian Benöhr; Christoph Meisner; Otmar D Wiestler; Johannes Dichgans; Lothar Kanz; Michael Bamberg; Michael Weller
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

2.  NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

Authors:  Ulrich Herrlinger; Wilhelm Küker; Martin Uhl; Hans-Peter Blaicher; Hans-Otto Karnath; Lothar Kanz; Michael Bamberg; Michael Weller
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

3.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

4.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Authors:  Wolfgang Wick; Christian Hartmann; Corinna Engel; Mandy Stoffels; Jörg Felsberg; Florian Stockhammer; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Richard Meyermann; Marion Rapp; Christof Meisner; Rolf D Kortmann; Torsten Pietsch; Otmar D Wiestler; Ulrike Ernemann; Michael Bamberg; Guido Reifenberger; Andreas von Deimling; Michael Weller
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

5.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Authors:  Michael Weller; Bettina Müller; Rainer Koch; Michael Bamberg; Peter Krauseneck
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

Review 6.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

7.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Authors:  Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

8.  Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

Authors:  Michael Weller; Hilmar Berger; Christian Hartmann; Johannes Schramm; Manfred Westphal; Matthias Simon; Roland Goldbrunner; Dietmar Krex; Joachim P Steinbach; Christoph B Ostertag; Markus Loeffler; Torsten Pietsch; Andreas von Deimling
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.